Eicosanoids and Hypertension Pharmacology
Eicosanoids and Hypertension Pharmacology is a research topic within Biochemistry. Science Explorer counts 36k research works in it since 1950. 10.0% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the metabolism, function, and therapeutic implications of arachidonic acid derivatives, particularly epoxyeicosatrienoic acids (EETs), cytochrome P450 enzymes, and soluble epoxide hydrolase. The research covers their roles in cardiovascular function, inflammation, hypertension, and potential as therapeutic targets.
- Arachidonic Acid
- Epoxyeicosatrienoic Acids
- Cytochrome P450
- Soluble Epoxide Hydrolase
- Cardiovascular Function
- Inflammation
- Hypertension
- Eicosanoids
- Metabolism
- Therapeutic Target
- Research works
- 36k fractional, since 1950
- In the world top 10%
- 3.6k per year above
- Top-10% rate
- 10.0% share of its works in the world top 10%
- Growth, 2018-21 → 2022-25
- -5% the tick is no change
- Largest producer
China
32% of the 10 largest, 2022-now
Which countries lead Eicosanoids and Hypertension Pharmacology research?
By volume, China and the United States publish the most (709 and 707 works in 2022-now).
By volume, 2022-now
- 1
China 709 works
- 2
United States 707 works
- 3
Russia 138 works
- 4
Japan 137 works
- 5
India 135 works
- 6
Germany 109 works
- 7
Italy 85 works
- 8
United Kingdom 77 works
- 9
South Korea 76 works
- 10
Spain 61 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Eicosanoids and Hypertension Pharmacology research?
By volume in 2022-now, Russian Academy of Sciences publishes the most Eicosanoids and Hypertension Pharmacology research, followed by Harvard University and University of California, Davis.
By volume, 2022-now
- 1
Russian Academy of Sciences
Russia 32 works
- 2
Harvard University
United States 27 works
- 3
University of California, Davis
United States 25 works
- 4
National Institutes of Health
United States 18 works
- 5
University of Alberta
Canada 13 works
- 6
Huazhong University of Science and Technology
China 13 works
- 7
University of North Carolina at Chapel Hill
United States 13 works
- 8
Capital Medical University
China 13 works
- 9
Central South University
China 12 works
- 10
Peking University
China 12 works
Who are the leading researchers in Eicosanoids and Hypertension Pharmacology?
The most-cited researchers publishing on Eicosanoids and Hypertension Pharmacology include George Davey Smith, Walter Churchill Willett and Guido Kroemer.
- 1
George Davey Smith
United Kingdom 435k citations
- 2
Walter Churchill Willett
United States 411k citations
- 3
Guido Kroemer
France 386k citations
- 4
John J.V. McMurray
United Kingdom 349k citations
- 5
Hermann Brenner
Germany 343k citations
- 6
Shizuo Akira
Japan 342k citations
- 7
Emelia J. Benjamin
United States 341k citations
- 8
Jun Wang
China 340k citations
- 9
Giuseppe Remuzzi
Italy 328k citations
- 10
Matthias Egger
Switzerland 326k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Eicosanoids and Hypertension Pharmacology research done?
The largest centres of Eicosanoids and Hypertension Pharmacology research in 2022-now are Beijing (China), Shanghai (China), Moscow (Russia) and Tokyo (Japan). Among places with at least 20 works in it, it is an unusually large share of all research in Davis.
Largest cities, 2022-now
Where it is the local speciality
- DavisUS · 26.2 works12×
Location quotient: how much more of its research is in Eicosanoids and Hypertension Pharmacology than the world average.
Where is the best place to study Eicosanoids and Hypertension Pharmacology?
Among universities, judged by research, Harvard University, University of California, Davis and Karolinska Institutet score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.
Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.
Every institution in Eicosanoids and Hypertension Pharmacology, country by countryIs Eicosanoids and Hypertension Pharmacology research growing?
Output in 2022-2025 was 5% lower than in 2018-2021, peaking in 2008.
The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.
Its share of all research
Growing output can still be a shrinking share: all of science grows. This is Eicosanoids and Hypertension Pharmacology as a percentage of every work published that year, 0.013% in 2024.
Fractional works of Eicosanoids and Hypertension Pharmacology over all fractional works that year. How the balance of science has shifted.
How much of it reaches the world top 10%
Year by year.
Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.
Discussion
Ask a question or share a note about Eicosanoids and Hypertension Pharmacology. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.